NP
VYNT

NorthRock Partners’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

NorthRock Partners’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,766
Closed -$11K – 356
2022
Q3 		$11K Hold
3,766
– – ﹤0.01% 299
2022
Q2 		$17K Hold
3,766
– – ﹤0.01% 302
2022
Q1 		$27K Hold
3,766
– – ﹤0.01% 334
2021
Q4 		$25K Hold
3,766
– – ﹤0.01% 333
2021
Q3 		$44K Hold
3,766
– – ﹤0.01% 278
2021
Q2 		$70K Buy
+3,766
New +$70.2K 0.01% 249

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

NorthRock Partners's VYNT Position: Q4 2022 in Review

NorthRock Partners sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2022, closing a stake of 3,766 shares — an estimated $11K sold.

NorthRock Partners first reported a position in VYNT in Q2 2021 and held it in 6 quarters. The position peaked at $70K in Q2 2021. 17 funds tracked by Wall St. Rank hold VYNT as of Q4 2022.

  • NorthRock Partners reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • NorthRock Partners sold 3,766 Vyant Bio, Inc. Common Stock shares in Q4 2022, an estimated $11K.
  • NorthRock Partners first reported a position in Vyant Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • NorthRock Partners's Vyant Bio, Inc. Common Stock position peaked at $70K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2022.

Based on NorthRock Partners's 13F filing for Q4 2022, filed 1 Feb 2023.